Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical TrialPatricia M. Flynn, Maxensia Owor, Susan A. Fiscus et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2017Cited by 219
Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum ComponentPatricia M. Flynn, Taha E. Taha, Mae Cababasay et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2021Cited by 63
Raltegravir Pharmacokinetics in Neonates Following Maternal DosingDiana F. Clarke, Mark Mirochnick, Edward P. Acosta et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2014Cited by 45
Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) TrialJim Aizire, Kristina M. Brooks, Mark Mirochnick et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2020Cited by 6